Myriad Genetics, Inc.
Market Cap
$446.97M
P/E Ratio
-1.21
EPS
$-3.95
Dividend Yield
0.00%
52-Week Range
$3.76 — $10.30
Volume
2.00M
Avg Volume
1.34M
Beta
1.93
P/E (TTM)
-1.21
Forward P/E
86.48
PEG Ratio
-0.14
P/S (TTM)
0.55
P/B (TTM)
1.23
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.80%
ROA (TTM)
-0.52%
ROIC
—
Gross Margin
0.70%
Operating Margin
-0.32%
Net Margin
—
Debt/Equity
0.57
Current Ratio
2.49
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-1.23%
EPS Growth (5Y)
-0.59%
Sales Growth (3Y)
+0.07%
Sales Growth (5Y)
+0.06%
EPS Est (This Year)
$0.06
EPS Est (Next Year)
$0.11
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$1.60
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
93.21M
Float
88.67M
Free Float %
95.13%
RSI (14)
33.33
SMA 20
$5.64
SMA 50
$6.33
SMA 200
$6.32
ATR (14)
0.27
Volatility (Week)
0.02%
Volatility (Month)
0.02%
Pattern
Doji
1 Day
+0.20%
1 Week
-4.87%
1 Month
-22.80%
3 Months
-19.37%
6 Months
-17.93%
1 Year
—
YTD
-17.26%
All-Time High
$15.47
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
NASDAQ
IPO Date
1995-10-06
Employees
2700
CEO
Samraat S. Raha
Index Membership
—
Website
https://myriad.com
Myriad Genetics, Inc. (MYGN) is a healthcare company in the medical - diagnostics & research industry listed on the NASDAQ. With a market capitalization of $446.97M, a P/E ratio of -1.21, MYGN is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare MYGN against other stocks using dozens of fundamental and technical filters.
Myriad Genetics, Inc. (MYGN) has a trailing twelve-month (TTM) P/E ratio of -1.21. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Myriad Genetics, Inc. (MYGN) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Myriad Genetics, Inc. (MYGN) has a market capitalization of $446.97 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Myriad Genetics, Inc. (MYGN) has returned -17.26% year-to-date. Past performance does not guarantee future results, but these figures reflect the stock's recent price trajectory relative to the broader market.